Targeted therapy prolongs life in patients with HER2-positive breast cancer
Friday, December 11, 2009 - 16:21
in Health & Medicine
Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to new research.